PRGO Stock Analysis: Perrigo | NYSE
Drug Manufacturers - Specialty & Generic | NYSE, USA | Market Cap: 1.735m USD | 12M Return: -39% | IE00BGH1M568 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 32.1M
EPS Trend: 14.9%
Qual. Beats: 1
Rev. Trend: -97.6%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Perrigo Company plc (NYSE: PRGO) is a Dublin-based provider of over-the-counter (OTC) consumer self-care products, operating through Consumer Self-Care Americas and Consumer Self-Care International segments. Founded in 1887 and headquartered in Ireland, the company sells branded and private-label health and wellness items across upper respiratory, nutrition (including infant formula and electrolyte beverages), digestive health, pain and sleep, oral care, skin care, womens health, and vitamins/minerals/supplements categories, under brands such as Mederma, Plackers, REACH, Nasonex, Prevacid24HR, Opill, Solpadeine, and ellaOne.
Distribution spans retail drug, supermarket, and mass merchandise chains, e-commerce, wholesalers, pharmacies, and para-pharmacies, with the company also offering contract manufacturing services. Perrigo is widely recognized as one of the worlds largest manufacturers of private-label/store-brand OTC products, a business model in which retailers sell the companys formulations under their own labels, complementing its portfolio of owned brands.
- Opill OTC contraceptive adoption drives segment growth
- Store brand pricing pressure impacts Consumer Self-Care margins
- European segment revenue declines on weak demand
| Net Income: -1.73b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -0.24 > 1.0 |
| NWC/Revenue: 33.70% < 20% (prev 34.42%; Δ -0.72% < -1%) |
| CFO/TA 0.03 > 3% & CFO 251.8m > Net Income -1.73b |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.32 > 1.5 & < 3 |
| Outstanding Shares: last quarter (139.6m) vs 12m ago 1.01% < -2% |
| Gross Margin: 33.26% > 18% (prev 35.73%; Δ -2.46% > 0.5%) |
| Asset Turnover: 46.83% > 50% (prev 42.86%; Δ 3.97% > 0%) |
| Interest Coverage Ratio: -9.11 > 6 (EBIT TTM -1.49b / Interest Expense TTM 163.1m) |
| A: 0.18 (Total Current Assets 2.45b - Total Current Liabilities 1.05b) / Total Assets 7.61b |
| B: -0.53 (Retained Earnings -4.00b / Total Assets 7.61b) |
| C: -0.17 (EBIT TTM -1.49b / Avg Total Assets 8.85b) |
| D: 0.49 (Book Value of Equity 2.52b / Total Liabilities 5.09b) |
| Altman-Z'' = -1.12 = CCC |
| DSRI: 1.12 (Receivables 761.2m/706.6m, Revenue 4.14b/4.33b) |
| GMI: 1.07 (GM 35.73% / 33.26%) |
| AQI: 0.90 (AQ_t 0.57 / AQ_t-1 0.63) |
| SGI: 0.96 (Revenue 4.14b / 4.33b) |
| TATA: -0.26 (NI -1.73b - CFO 251.8m) / TA 7.61b) |
| Beneish M = -2.98 (Cap -4..+1) = A |
As of August 09, 2026, the stock is trading at USD 12.84 with a total of 2,107,035 shares traded. Over the past week, the price has changed by +27.00%, over one month by +14.75%, over three months by +12.41% and over the past year by -38.95%.
Current recommended Stop Loss: 12.00 (which is 6.5% or 1.3 ATR below the current price).
Perrigo has received a consensus analysts rating of 3.80. Therefore, it is recommended to hold PRGO.
- StrongBuy: 1
- Buy: 2
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 16.5 | 28.5% |
P/E Forward = 5.0607
P/S = 0.4186
P/B = 0.5969
P/EG = 1.1418
Revenue TTM = 4.14b USD
EBIT TTM = -1.49b USD
EBITDA TTM = -1.35b USD
Long Term Debt = 3.60b USD (from longTermDebt, last fiscal year)
Short Term Debt = 11.4m USD (from shortTermDebt, last quarter)
Debt = 3.79b USD (corrected: LT Debt 3.60b + ST Debt 11.4m) + Leases 173.0m
Net Debt = 3.39b USD (calculated: Debt 3.79b - CCE 399.7m)
Enterprise Value = 5.12b USD (1.74b + Debt 3.79b - CCE 399.7m)
Interest Coverage Ratio = -9.11 (Ebit TTM -1.49b / Interest Expense TTM 163.1m)
EV/FCF = 29.28x (Enterprise Value 5.12b / FCF TTM 175.0m)
FCF Yield = 3.42% (FCF TTM 175.0m / Enterprise Value 5.12b)
FCF Margin = 4.22% (FCF TTM 175.0m / Revenue TTM 4.14b)
Net Margin = -41.85% (Net Income TTM -1.73b / Revenue TTM 4.14b)
Gross Margin = 33.26% ((Revenue TTM 4.14b - Cost of Revenue TTM 2.77b) / Revenue TTM)
Gross Margin QoQ = 30.69% (prev 33.58%)
Tobins Q-Ratio = 0.67 (Enterprise Value 5.12b / Total Assets 7.61b)
Interest Expense / Debt = 4.31% (Interest Expense 163.1m / Debt 3.79b)
Taxrate = 16.03% (16.9m / 105.4m)
NOPAT = -1.25b (EBIT -1.49b * (1 - 16.03%)) [loss with tax shield]
Current Ratio = 2.32 (Total Current Assets 2.45b / Total Current Liabilities 1.05b)
Debt / Equity = 1.51 (Debt 3.79b / totalStockholderEquity, last quarter 2.52b)
Debt / EBITDA = -2.52 (negative EBITDA) (Net Debt 3.39b / EBITDA -1.35b)
Debt / FCF = 19.36 (Net Debt 3.39b / FCF TTM 175.0m)
Total Stockholder Equity = 3.10b (last 4 quarters mean from totalStockholderEquity)
RoA = -19.60% (Net Income -1.73b / Total Assets 7.61b)
RoE = -55.97% (Net Income TTM -1.73b / Total Stockholder Equity 3.10b)
RoCE = -22.17% (EBIT -1.49b / Capital Employed (Equity 3.10b + L.T.Debt 3.60b))
RoIC = -19.63% (negative operating profit) (NOPAT -1.25b / Invested Capital 6.36b)
WACC = 5.50% (E(1.74b)/V(5.52b) * Re(9.61%) + D(3.79b)/V(5.52b) * Rd(4.31%) * (1-Tc(0.16)))
Discount Rate = 9.61% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 91.24 | Cagr: 0.64%
[DCF] Terminal Value 73.10% ; FCFF base≈207.7m ; Y1≈182.1m ; Y5≈147.1m
[DCF] Fair Price = N/A (negative equity: EV 2.36b - Net Debt 3.39b = -1.03b; debt exceeds intrinsic value)
EPS Correlation: 14.91 | EPS CAGR: 1.33% | SUE: 0.84 | # QB: 1
Revenue Correlation: -97.60 | Revenue CAGR: -4.04% | SUE: 0.49 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.57 | Chg30d=+0.44% | Revisions=-17% | Analysts=4
EPS current Year (2026-12-31): EPS=2.11 | Chg30d=+0.09% | Revisions=-17% | GrowthEPS=-23.3% | GrowthRev=-4.5%
EPS next Year (2027-12-31): EPS=2.37 | Chg30d=+0.17% | Revisions=+0% | GrowthEPS=+12.1% | GrowthRev=+1.0%
[Analyst] Revisions Ratio: -15% (up=4, down=6)